Amgen’s Easy “On-Body” Tepezza Shot Crushes Phase 3 — Viridian Stock Plunges

Viridian shares fell after Amgen’s new, easy Tepezza shot showed strong results for Thyroid Eye Disease.

Amgen’s Easy “On-Body” Tepezza Shot Crushes Phase 3 — Viridian Stock Plunges
Credit: Viridian Therapeutics
Already have an account? Sign in.